Identifying and validating subtypes within major psychiatric disorders based on frontal-posterior functional imbalance via deep learning

Miao Chang, Fay Y Womer, Xiaohong Gong, Xi Chen, Lili Tang, Ruiqi Feng, Shuai Dong, Jia Duan, Yifan Chen, Ran Zhang, Yang Wang, Sihua Ren, Yi Wang, Jujiao Kang, Zhiyang Yin, Yange Wei, Shengnan Wei, Xiaowei Jiang, Ke Xu, Bo Cao, Yanbo Zhang, Weixiong Zhang, Yanqing Tang, Xizhe Zhang, Fei Wang, Miao Chang, Fay Y Womer, Xiaohong Gong, Xi Chen, Lili Tang, Ruiqi Feng, Shuai Dong, Jia Duan, Yifan Chen, Ran Zhang, Yang Wang, Sihua Ren, Yi Wang, Jujiao Kang, Zhiyang Yin, Yange Wei, Shengnan Wei, Xiaowei Jiang, Ke Xu, Bo Cao, Yanbo Zhang, Weixiong Zhang, Yanqing Tang, Xizhe Zhang, Fei Wang

Abstract

Converging evidence increasingly implicates shared etiologic and pathophysiological characteristics among major psychiatric disorders (MPDs), such as schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD). Examining the neurobiology of the psychotic-affective spectrum may greatly advance biological determination of psychiatric diagnosis, which is critical for the development of more effective treatments. In this study, ensemble clustering was developed to identify subtypes within a trans-diagnostic sample of MPDs. Whole brain amplitude of low-frequency fluctuations (ALFF) was used to extract the low-dimensional features for clustering in a total of 944 participants: 581 psychiatric patients (193 with SZ, 171 with BD, and 217 with MDD) and 363 healthy controls (HC). We identified two subtypes with differentiating patterns of functional imbalance between frontal and posterior brain regions, as compared to HC: (1) Archetypal MPDs (60% of MPDs) had increased frontal and decreased posterior ALFF, and decreased cortical thickness and white matter integrity in multiple brain regions that were associated with increased polygenic risk scores and enriched risk gene expression in brain tissues; (2) Atypical MPDs (40% of MPDs) had decreased frontal and increased posterior ALFF with no associated alterations in validity measures. Medicated Archetypal MPDs had lower symptom severity than their unmedicated counterparts; whereas medicated and unmedicated Atypical MPDs had no differences in symptom scores. Our findings suggest that frontal versus posterior functional imbalance as measured by ALFF is a novel putative trans-diagnostic biomarker differentiating subtypes of MPDs that could have implications for precision medicine.

Conflict of interest statement

The authors declare that they have no conflict of interest.

© 2020. The Author(s).

Figures

Fig. 1. Schematic of using deep learning-based…
Fig. 1. Schematic of using deep learning-based hierarchical clustering to define clusters of MPDs.
Step one: identification of significant functional alterations in MPDs and using AutoEncoder to reduce the dimension of the identified alterations to d ∈ [2,10]. Step two: for each of the nine low-dimensional data from step one, we obtained nine different class labels based on clustering analyses, and five clusters (cluster A, B, C, D, and E) were identified. Step three: we performed the clusters merging process according to six runs of clustering and obtained two final subtypes. Furthermore, the subtypes varied in patterns of amplitude of low-frequency fluctuation alterations as compared to HC (voxel p < 0.001 with Gaussian random field correction for cluster p < 0.05). MPD major psychiatric disorder; HC healthy control; L left; R right; d dimension.
Fig. 2. Significant differences in (a) cortical…
Fig. 2. Significant differences in (a) cortical thickness and (b) white matter integrity between Archetypal MPDs and healthy controls.
Significance level was set to voxel p < 0.001 with Gaussian random field correction for cluster p < 0.05. The color bar represents t value. MPD major psychiatric disorder.
Fig. 3. The variance ( y -axis)…
Fig. 3. The variance (y-axis) of case-control status explained by the PRS-SZBD and PRS-MDD in Archetypal and Atypical MPDs.
x-axis represents p value threshold, y-axis represents PRS model fit: R2 (Nagelkerke’s). The bars represent ten best-fit PRS scores calculated at different p value threshold. ***p < 0.001; **p < 0.01. PRS-SZBD, polygenetic risk score of schizophrenia and bipolar disorder, PRS-MDD, polygenetic risk score of major depressive disorder. MPD major psychiatric disorder.
Fig. 4. Differentially expressed risk genes across…
Fig. 4. Differentially expressed risk genes across 53 tissues in (a) Archetypal and (b) Atypical MPDs.
MPD major psychiatric disorder.
Fig. 5. Significant differences in HAMD factors…
Fig. 5. Significant differences in HAMD factors and BPRS factor scores between medicated and unmedicated patients in Archetypal and Atypical MPDs.
The significance level was set to p < 0.05 with false discovery rate correction. Vertical black lines show the standard errors of the means. ***p < 0.001; **p < 0.01. HAMD Hamilton Depression Scale; BPRS Brief Psychiatric Rating Scale; MPD major psychiatric disorder.

References

    1. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371–9. doi: 10.1016/S0140-6736(12)62129-1.
    1. Garcia-Rizo C, Kirkpatrick B, Fernandez-Egea E, Oliveira C, Bernardo M. Abnormal glycemic homeostasis at the onset of serious mental illnesses: a common pathway. Psychoneuroendocrinology. 2016;67:70–5. doi: 10.1016/j.psyneuen.2016.02.001.
    1. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21:14. doi: 10.1038/mp.2016.3.
    1. Goodkind M, Eickhoff SB, Oathes DJ, Jiang Y, Chang A, Jones-Hagata LB, et al. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry. 2015;72:305–15. doi: 10.1001/jamapsychiatry.2014.2206.
    1. Chang M, Womer FY, Edmiston EK, Bai C, Zhou Q, Jiang X, et al. Neurobiological commonalities and distinctions among three major psychiatric diagnostic categories: a structural MRI study. Schizophr Bull. 2018;44:65–74. doi: 10.1093/schbul/sbx028.
    1. Chang M, Edmiston EK, Womer FY, Zhou Q, Wei S, Jiang X, et al. Spontaneous low-frequency fluctuations in the neural system for emotional perception in major psychiatric disorders: amplitude similarities and differences across frequency bands. J Psychiatry Neurosci. 2019;44:132–41. doi: 10.1503/jpn.170226.
    1. Clementz BA, Sweeney JA, Hamm JP, Ivleva EI, Ethridge LE, Pearlson GD, et al. Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry. 2016;173:373–84. doi: 10.1176/appi.ajp.2015.14091200.
    1. Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23:28–38. doi: 10.1038/nm.4246.
    1. Ivleva EI, Clementz BA, Dutcher AM, Arnold SJM, Jeon-Slaughter H, Aslan S, et al. Brain structure biomarkers in the psychosis biotypes: findings from the bipolar-schizophrenia network for intermediate phenotypes. Biol Psychiatry. 2017;82:26–39. doi: 10.1016/j.biopsych.2016.08.030.
    1. Meda SA, Clementz BA, Sweeney JA, Keshavan MS, Tamminga CA, Ivleva EI, et al. Examining functional resting-state connectivity in psychosis and its subgroups in the bipolar-schizophrenia network on intermediate phenotypes cohort. Biol Psychiatry Cognit Neurosci Neuroimaging. 2016;1:488–97. doi: 10.1016/j.bpsc.2016.07.001.
    1. Barch DM. Biotypes: promise and pitfalls. Biol Psychiatry. 2017;82:2–3. doi: 10.1016/j.biopsych.2017.04.012.
    1. Wager TD, Atlas LY, Lindquist MA, Roy M, Woo CW, Kross E. An fMRI-based neurologic signature of physical pain. N Engl J Med. 2013;368:1388–97. doi: 10.1056/NEJMoa1204471.
    1. Patriat R, Molloy EK, Meier TB, Kirk GR, Nair VA, Meyerand ME, et al. The effect of resting condition on resting-state fMRI reliability and consistency: a comparison between resting with eyes open, closed, and fixated. Neuroimage. 2013;78:463–73. doi: 10.1016/j.neuroimage.2013.04.013.
    1. Zuo XN, Di Martino A, Kelly C, Shehzad ZE, Gee DG, Klein DF, et al. The oscillating brain: complex and reliable. Neuroimage. 2010;49:1432–45. doi: 10.1016/j.neuroimage.2009.09.037.
    1. Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995;34:537–41. doi: 10.1002/mrm.1910340409.
    1. Krishnan GP, Gonzalez OC, Bazhenov M. Origin of slow spontaneous resting-state neuronal fluctuations in brain networks. Proc Natl Acad Sci USA. 2018;115:6858–63. doi: 10.1073/pnas.1715841115.
    1. Nugent AC, Martinez A, D'Alfonso A, Zarate CA, Theodore WH. The relationship between glucose metabolism, resting-state fMRI BOLD signal, and GABAA-binding potential: a preliminary study in healthy subjects and those with temporal lobe epilepsy. J Cereb Blood Flow Metab. 2015;35:583–91. doi: 10.1038/jcbfm.2014.228.
    1. Noda A, Ohba H, Kakiuchi T, Futatsubashi M, Tsukada H, Nishimura S. Age-related changes in cerebral blood flow and glucose metabolism in conscious rhesus monkeys. Brain Res. 2002;936:76–81. doi: 10.1016/S0006-8993(02)02558-1.
    1. Zang YF, He Y, Zhu CZ, Cao QJ, Sui MQ, Liang M, et al. Altered baseline brain activity in children with ADHD revealed by resting-state functional MRI. Brain Dev. 2007;29:83–91. doi: 10.1016/j.braindev.2006.10.001.
    1. Zuo XN, Xing XX. Test-retest reliabilities of resting-state FMRI measurements in human brain functional connectomics: a systems neuroscience perspective. Neurosci Biobehav Rev. 2014;45:100–18. doi: 10.1016/j.neubiorev.2014.05.009.
    1. Zuo XN, Xu T, Milham MP. Harnessing reliability for neuroscience research. Nat Hum Behav. 2019;3:768–71. doi: 10.1038/s41562-019-0655-x.
    1. Turner JA, Chen H, Mathalon DH, Allen EA, Mayer AR, Abbott CC, et al. Reliability of the amplitude of low-frequency fluctuations in resting state fMRI in chronic schizophrenia. Psychiatry Res. 2012;201:253–5. doi: 10.1016/j.pscychresns.2011.09.012.
    1. Meda SA, Wang Z, Ivleva EI, Poudyal G, Keshavan MS, Tamminga CA, et al. Frequency-specific neural signatures of spontaneous low-frequency resting state fluctuations in psychosis: evidence from bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) consortium. Schizophr Bull. 2015;41:1336–48. doi: 10.1093/schbul/sbv064.
    1. Bellman R. Dynamic programming. Princeton: Princeton University Press; 1957. Rand corporation; p. 342.
    1. Hinton GE, Salakhutdinov RR. Reducing the dimensionality of data with neural networks. Science. 2006;313:504–7. doi: 10.1126/science.1127647.
    1. Yan CG, Wang XD, Zuo XN, Zang YF. DPABI: data processing & analysis for (resting-state) brain imaging. Neuroinformatics. 2016;14:339–51. doi: 10.1007/s12021-016-9299-4.
    1. Euesden J, Lewis CM, O'Reilly PF. PRSice: Polygenic Risk Score software. Bioinformatics. 2015;31:1466–8. doi: 10.1093/bioinformatics/btu848.
    1. Consortium GT. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648–60. doi: 10.1126/science.1262110.
    1. Xu K, Liu H, Li H, Tang Y, Womer F, Jiang X, et al. Amplitude of low-frequency fluctuations in bipolar disorder: a resting state fMRI study. J Affect Disord. 2014;152–4:237–42. doi: 10.1016/j.jad.2013.09.017.
    1. Liu J, Ren L, Womer FY, Wang J, Fan G, Jiang W, et al. Alterations in amplitude of low frequency fluctuation in treatment-naive major depressive disorder measured with resting-state fMRI. Hum Brain Mapp. 2014;35:4979–88. doi: 10.1002/hbm.22526.
    1. Pearlson GD, Clementz BA, Sweeney JA, Keshavan MS, Tamminga CA. Does biology transcend the symptom-based boundaries of psychosis? Psychiatr Clin N Am. 2016;39:165–74. doi: 10.1016/j.psc.2016.01.001.
    1. Ivleva EI, Bidesi AS, Keshavan MS, Pearlson GD, Meda SA, Dodig D, et al. Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Am J Psychiatry. 2013;170:1285–96. doi: 10.1176/appi.ajp.2013.13010126.
    1. Skudlarski P, Schretlen DJ, Thaker GK, Stevens MC, Keshavan MS, Sweeney JA, et al. Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. Am J Psychiatry. 2013;170:886–98. doi: 10.1176/appi.ajp.2013.12111448.
    1. Kumar J, Iwabuchi S, Oowise S, Balain V, Palaniyappan L, Liddle PF. Shared white-matter dysconnectivity in schizophrenia and bipolar disorder with psychosis. Psychol Med. 2015;45:759–70. doi: 10.1017/S0033291714001810.
    1. Ramaker RC, Bowling KM, Lasseigne BN, Hagenauer MH, Hardigan AA, Davis NS, et al. Post-mortem molecular profiling of three psychiatric disorders. Genome Med. 2017;9:72. doi: 10.1186/s13073-017-0458-5.
    1. Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardinas AF, et al. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nat Genet. 2019;51:659–74.
    1. Voineskos AN, Lerch JP, Felsky D, Tiwari A, Rajji TK, Miranda D, et al. The ZNF804A gene: characterization of a novel neural risk mechanism for the major psychoses. Neuropsychopharmacology. 2011;36:1871–8. doi: 10.1038/npp.2011.72.
    1. Ahmed M, Cannon DM, Scanlon C, Holleran L, Schmidt H, McFarland J, et al. Progressive brain atrophy and cortical thinning in schizophrenia after commencing clozapine treatment. Neuropsychopharmacology. 2015;40:2409–17. doi: 10.1038/npp.2015.90.
    1. Lesh TA, Tanase C, Geib BR, Niendam TA, Yoon JH, Minzenberg MJ, et al. A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. JAMA Psychiatry. 2015;72:226–34. doi: 10.1001/jamapsychiatry.2014.2178.
    1. Leung M, Cheung C, Yu K, Yip B, Sham P, Li Q, et al. Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. Schizophr Bull. 2011;37:199–211. doi: 10.1093/schbul/sbp099.
    1. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17:149–60. doi: 10.1002/wps.20516.
    1. Wang Q, Chen R, Cheng F, Wei Q, Ji Y, Yang H, et al. A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data. Nat Neurosci. 2019;22:691–9. doi: 10.1038/s41593-019-0382-7.
    1. Sui J, Qi S, van Erp TGM, Bustillo J, Jiang R, Lin D, et al. Multimodal neuromarkers in schizophrenia via cognition-guided MRI fusion. Nat Commun. 2018;9:3028. doi: 10.1038/s41467-018-05432-w.
    1. Sui J, Jiang R, Bustillo J, Calhoun V. Neuroimaging-based individualized prediction of cognition and behavior for mental disorders and health: methods and promises. Biol Psychiatry. 2020;S0006-3223:30111–6.
    1. Zhi D, Calhoun VD, Lv L, Ma X, Ke Q, Fu Z, et al. Aberrant dynamic functional network connectivity and graph properties in major depressive disorder. Front Psychiatry. 2018;9:339. doi: 10.3389/fpsyt.2018.00339.

Source: PubMed

Подписаться